Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft.
The combination of Tumour Necrosis Factor (TNF) and mitoxantrone was evaluated for potential chemotherapeutic effect against a human ovarian cancer cell line A2774 hetero-transplanted in female nude mice. Both antitumour efficacy (relative survival and reduction of ascites) and toxicity (weight loss and liver toxicity) of TNF alone, mitoxantrone alone or TNF + mitoxantrone were evaluated. A significant difference (P < 0.002) was observed only among animals bearing tumours treated with mitoxantrone (0.012 mg/Kg) + TNF (5 x 10(5) U/Kg) and controls. No cytotoxic effects were observed for this combination. These observations provide a rationale for further evaluation of TNF + mitoxantrone based regimes for the treatment of recurrent ovarian cancer.
Noviello
E
E
Department Experimental Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
Cimoli
G
G
Cosimi
A
A
Allievi
E
E
Galletti
P
P
Parodi
S
S
Russo
P
P
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007928:Lethal Dose 50; D051379:Mice; D008819:Mice, Nude; D008942:Mitoxantrone / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D008942:Mitoxantrone